Retrophin, Inc. (RTRX) was a big mover last session with its shares rising over 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock has remarkably gained nearly 87% in the past one-month time frame.
This biopharmaceutical company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate hasn’t been in trend either. Friday’s rally is encouraging though, so make sure to keep a close watch on this firm in the near future.
Retrophin currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Other well-placed biomedical stocks include Alexion Pharmaceuticals, Inc. (ALXN), Biogen Idec Inc. (BIIB) and Actelion Ltd. (ALIOF). While Alexion and Biogen sport a Zacks Rank #1 (Strong Buy), Actelion carries the same Zacks Rank as Retrophin.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment